Estimating age‐specific cumulative incidence for the 2009 influenza pandemic: a meta‐analysis of A(H1N1)pdm09 serological studies from 19 countries
Open Access
- 21 January 2013
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 7 (5) , 872-886
- https://doi.org/10.1111/irv.12074
Abstract
The global impact of the 2009 influenza A(H1N1) pandemic (H1N1pdm) is not well understood. We estimate overall and age-specific prevalence of cross-reactive antibodies to H1N1pdm virus and rates of H1N1pdm infection during the first year of the pandemic using data from published and unpublished H1N1pdm seroepidemiological studies. Primary aggregate H1N1pdm serologic data from each study were stratified in standardized age groups and evaluated based on when sera were collected in relation to national or subnational peak H1N1pdm activity. Seropositivity was assessed using well-described and standardized hemagglutination inhibition (HI titers ≥ 32 or ≥ 40) and microneutralization (MN ≥ 40) laboratory assays. The prevalence of cross-reactive antibodies to the H1N1pdm virus was estimated for studies using sera collected prior to the start of the pandemic (between 2004 and April 2009); H1N1pdm cumulative incidence was estimated for studies in which collected both pre- and post-pandemic sera; and H1N1pdm seropositivity was calculated from studies with post-pandemic sera only (collected between December 2009-June 2010). Data from 27 published/unpublished studies from 19 countries/administrative regions - Australia, Canada, China, Finland, France, Germany, Hong Kong SAR, India, Iran, Italy, Japan, Netherlands, New Zealand, Norway, Reunion Island, Singapore, United Kingdom, United States, and Vietnam - were eligible for inclusion. The overall age-standardized pre-pandemic prevalence of cross-reactive antibodies was 5% (95%CI 3-7%) and varied significantly by age with the highest rates among persons ≥ 65 years old (14% 95%CI 8-24%). Overall age-standardized H1N1pdm cumulative incidence was 24% (95%CI 20-27%) and varied significantly by age with the highest in children 5-19 (47% 95%CI 39-55%) and 0-4 years old (36% 95%CI 30-43%). Our results offer unique insight into the global impact of the H1N1 pandemic and highlight the need for standardization of seroepidemiological studies and for their inclusion in pre-pandemic preparedness plans. Our results taken together with recent global pandemic respiratory-associated mortality estimates suggest that the case fatality ratio of the pandemic virus was approximately 0.02%.Keywords
This publication has 60 references indexed in Scilit:
- Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling studyThe Lancet Infectious Diseases, 2012
- The Epidemiology of Interpandemic and Pandemic Influenza in Vietnam, 2007–2010American Journal of Epidemiology, 2012
- Low Level of Cross-Reactive Antibodies to Pandemic Influenza (H1N1) 2009 Virus in Humans in Pre-Pandemic Period in Maharashtra, IndiaIndian Journal of Virology, 2012
- Seroprevalence to Influenza A(H1N1) 2009 Virus—Where Are We?Clinical and Vaccine Immunology, 2011
- Seroprevalence of Pandemic 2009 (H1N1) Influenza A Virus among Schoolchildren and Their Parents in Tokyo, JapanClinical and Vaccine Immunology, 2011
- Immuno-epidemiologic Correlates of Pandemic H1N1 Surveillance Observations: Higher Antibody and Lower Cell-Mediated Immune Responses with Advanced AgeThe Journal of Infectious Diseases, 2010
- Preexisting Antibody Response against 2009 Pandemic Influenza H1N1 Viruses in the Taiwanese PopulationClinical and Vaccine Immunology, 2010
- The Infection Attack Rate and Severity of 2009 Pandemic H1N1 Influenza in Hong KongClinical Infectious Diseases, 2010
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Pandemic Potential of a Strain of Influenza A (H1N1): Early FindingsScience, 2009